You are here

P&T July 2012

Features

Editorial
A controversial bill to change the classification of the opioid hydrocodone from Schedule II to Schedule II might help decrease the incidence of drug abuse through stricter regulation of Schedule II products, or, as some groups claim, it might hinder access for patients with legitimate prescriptions.

Mortality rates for cardiovascular disease are higher in women than in men, but studies of women have been conducted less frequently. Current pharmacological and nonpharmacological treatment options for women with stable angina are reviewed.

Controversies in Practice
To Compound or Not to Compound That Is the Question
Preterm births have increased by 27% over the last decade in the U.S. The main ingredient in Makena, 17P, is less expensive at compounding pharmacies, but this method is not FDA-approved. The authors discuss the quality, safety, and use of Makena and compounded 17P; the potential for liability; cost considerations; and recommended restrictions for the product’s use.
Continuing Education Credit

Chronic nonmalignant pain, which affects millions of people, is the most common reason patients seek medical care. Both current and potential opioid analgesics are discussed, along with new technologies used to prevent abuse.

Departments

Medication Errors
The physical design of an organization’s workspace can enhance or diminish patient safety.
Prescription: Washington
Drug companies may be required to report shortages sooner, but the FDA legislation still lacks power.

FDA approvals, drug indications, and updates

Tazarotene (Fabior Foam) for acne; estradiol valerate and estradiol valerate/dienogest (Natazia) for heavy menstrual bleeding; and taliglucerase alfa (Elelyso) for Gaucher’s disease

Drug Forecast
Fospropofol disodium (Lusedra) for anesthesia sedation